IP Library Granted Patent US 9,266,734
Granted Patent B2
US 9,266,734 · App. 13/249,098 · Granted Feb 23, 2016

Chlorite formulations and methods of preparation and use thereof

Inventors: William Boulanger (Mahomet, IL); Arasteh Ari Azhir (Los Altos, CA)
Assignee: NEURALTUS PHARMACEUTICALS, INC.
C01B11/10A61K9/0019A61K33/00A61K47/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,266,734
App. No.
13/249,098
Granted
Feb 23, 2016
Kind
B2
Abstract

Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.

Claims (20)

1. A kit for treatment of neurodegenerative disease in a patient in need thereof comprising

(i) one or more unit doses of a pharmaceutically acceptable salt of chlorite;

(ii) a physiologically compatible buffer comprising phosphate in an amount sufficient to result in a pH between about 7 and about 9 when combined with said one or more unit doses;

(iii) physiological saline solution; and

(iv) instructions for treatment of neurodegenerative disease by intravenous administration of said one or more unit doses of a pharmaceutically acceptable salt of chlorite and said pH adjusting agent;

wherein said chlorite is purified to greater than about 95% chlorite ions to non-chlorite ions.

2. The kit of claim 1 , wherein said pharmaceutically acceptable salt of chlorite is sodium chlorite.

3. The kit of claim 2 , wherein said sodium chlorite is purified to greater than about 99% chlorite ions to non-chlorite ions.

4. The kit of claim 1 , wherein said one or more unit doses are in solution form.

5. The kit of claim 1 , wherein said one or more unit doses are in solid form.

6. The kit of claim 1 , wherein said one or more unit doses contain an amount of chlorate ions and have a ratio of chlorite ions to chlorate ions that is greater than 100:1.5.

7. The kit of claim 1 , wherein the one or more unit doses contain an amount of sulfate ions and have a ratio of chlorite ions to sulfate ions that is greater than 100:16.

8. The kit of claim 1 , wherein said physiologically compatible buffer is included in said one or more unit doses.

9. The kit of claim 1 , wherein said physiologically compatible buffer is separate from said one or more unit doses.

10. The kit of claim 1 , wherein said one or more unit doses and said physiologically compatible buffer are contained within said saline solution.

11. The kit of claim 1 , further comprising one or more syringes.

12. The kit of claim 1 , further comprising flexible packaging for intravenous administration.

13. The kit of claim 1 , comprising unit dosages for treatment for a period of about 4 weeks or less.

14. The kit of claim 1 , comprising unit dosages for treatment for a period of greater than about 4 weeks.

15. The kit of claim 1 , wherein the pharmaceutically acceptable salt of chlorite is substantially free of chlorine dioxide.

Assignments (5)
CHANGE OF NAME Recorded Sep 10, 2021
From: NEUVIVA, INC.
To: NEUVIVO, INC.
Reel/Frame 057471/0847 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2020
From: NORVIEL, VERNON A.
To: NEUVIVA, INC.
Reel/Frame 053425/0719 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2019
From: NEURALTUS PHARMACEUTICALS, INC.
To: NORVIEL, VERNON A.
Reel/Frame 051380/0353 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2011
From: BOULANGER, WILLIAM; AZHIR, ARASTEH ARI
To: TAIJI BIOMEDICAL, INC.
Reel/Frame 027056/0390 →
CHANGE OF NAME Recorded Oct 13, 2011
From: TAIJI BIOMEDICAL, INC.
To: NEURALTUS PHARMACEUTICALS, INC.
Reel/Frame 027059/0956 →
Continuity (3)
Division 11614859 · Dec 21, 2006
Provisional Application 60753497 · Dec 22, 2005
Related Publication 20120021069A1 · Jan 26, 2012